Latest Breaking News On - அம்புக்குறி மருந்துகள் இன்க் - Page 5 : comparemela.com
Antisense Oligonucleotides Market to Witness Heightened Revenue Growth During the Forecast Period 2027 – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
Nanotechnology Now - Press Release: Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
nanotech-now.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nanotech-now.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson (NYSE:JNJ), Arrowhead Research Corporation (NASDAQ:ARWR) - Arrowhead Receives $10M Option Exercise Fee From Janssen
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Operator
Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today s recorded presentation all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead Vince.
Vincent Anzalone
Vice President of Investor Relations
Thank you, Jessi. Good afternoon everyone. Thank you for joining us today to discuss Arrowhead s results for it s Fiscal 2021 Second Quarter ended March 31, 2021. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our pipeline; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, James Hassard, our Chief Commercial Officer, and Dr. James Hamilto
Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.88% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Growth Index that delivered a 6.17% and 1.19% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Opportunity Fund, in their Q1 2021 investor letter, mentioned Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), and shared their insights on the company. Arrowhead Pharmaceuticals, Inc. is a Pasadena, California-based biopharmaceutical company that currently has a $7.5 billion market capitalization. Since the beginning of the year, ARWR delivered a -5.17% return, while its 12-month gains are up by 113%. As of April 30, 2021, the stock closed at $72.76 per share.